Skip to main contentSkip to navigation
Sirius Investors

Cue Biopharma, Inc. (CUE) Investment Research Dashboard

About Cue Biopharma, Inc. (CUE) stock analysis

Get live CUE stock price $32.12, comprehensive Cue Biopharma, Inc. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time CUE stock data and investment insights.

32.12
2.93%Today
Market Cap
84.41M
Volume
148.25K
52W High
45.50
52W Low
4.98

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various ca...

Company Information

CEO
Shao-Lee Lin
Sector
Healthcare
Industry
Biotechnology
Employees
29

Contact Information

Address
40 Guest Street
Country
US

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Higher growth potential with elevated volatility (Beta: 2.46)

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Cue Biopharma, Inc. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Cue Biopharma, Inc.
  • Investors should consider how Cue Biopharma, Inc. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

84.41M

P/E Ratio (TTM)

-34.17

Beta

2.46

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

77/100 ⭐⭐⭐⭐⭐

Overall
+0.3%
NYSE
+0.7%
NASDAQ
-0.2%
Sector1D1W1MP/EScore
Financial Services+0.3%+1.5%+2.2%19.1
82/100⭐⭐⭐⭐⭐
Healthcare+0.3%+2.7%+1.5%23.5
77/100⭐⭐⭐⭐⭐
Real Estate+1.8%+4.6%+0.7%29.8
72/100⭐⭐⭐⭐⭐
Communication Services+0.7%-2.1%+2.2%21.8
70/100⭐⭐⭐⭐⭐
Basic Materials+0.9%+2.0%-0.3%25.0
60/100⭐⭐⭐⭐
Consumer Defensive+0.8%+1.0%-0.2%28.7
55/100⭐⭐⭐⭐
Utilities-0.7%+2.5%-1.9%25.2
49/100⭐⭐⭐
Energy-0.2%-0.4%-2.4%19.6
42/100⭐⭐⭐
Consumer Cyclical+0.3%-1.6%-4.0%43.3
17/100
Industrials-0.5%-0.1%-8.9%30.4
15/100
Technology-1.6%-0.8%-5.3%42.2
12/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-27.